Skip to main content
Avantor Inc (AVTR)
Drugs Health Care
Stock AI

Avantor Inc. Welcomes Jerry Porreca as Executive Vice President of Quality and Regulatory

Last updated: May 19, 2026
Taurigo

Avantor Inc. (NYSE: AVTR), a prominent global provider of essential products and services to the life sciences and advanced technology sectors, has announced a significant addition to its leadership team. Effective May 19, 2026, Gerard (Jerry) Porreca has been appointed as the new Executive Vice President of Quality and Regulatory. This strategic move comes as Avantor continues to enhance its commitment to quality assurance and regulatory compliance across its diverse range of operations.

1. A Seasoned Executive with Extensive Experience

Mr. Porreca brings a wealth of expertise to Avantor, boasting a robust background in quality, regulatory affairs, and compliance within the life sciences, medical technology, and healthcare industries. His extensive career includes pivotal roles at several industry-leading companies. Prior to joining Avantor, he served as the head of Quality and Regulatory at Getinge, where he effectively guided the organization through complex global product approvals and navigated intricate regulatory challenges across different regions, including the U.S., European Union Medical Device Regulation (EU MDR), and China.

His previous experience includes senior executive positions at Becton Dickinson and Company, C.R. Bard, Inc., and Smith+Nephew plc, all of which have equipped him with the skills necessary to lead Avantor's global quality assurance and regulatory affairs.

2. A Vision for Quality and Reliability

Emmanuel Ligner, Avantor's President and CEO, expressed enthusiasm about the strategic appointment, stating, "Delivering solutions that meet the highest standards of quality and reliability makes Avantor a trusted partner at every stage of the scientific journey." Ligner emphasized that Porreca's deep knowledge of global quality systems and complex regulatory landscapes will be essential as Avantor seeks to scale its operations and provide mission-critical solutions to its customers.

3. Commitment to Accelerating Life-Changing Breakthroughs

In his new role, Mr. Porreca will oversee quality assurance, quality systems, and regulatory affairs across all of Avantor's business units. He articulated his vision, saying, "In the life sciences and advanced technology sectors, quality and regulatory excellence are not just requirements—they are a key value proposition for our customers. I look forward to working with our global teams to further strengthen our quality systems and leverage data-driven insights to help our customers accelerate the delivery of life-changing breakthroughs to patients worldwide."

4. About Avantor

Avantor Inc. is a leading life science tools company and a global provider of mission-critical products and services dedicated to the life sciences and advanced technology industries. With a commitment to collaboration, Avantor works alongside customers throughout the scientific journey to facilitate breakthroughs in medicine, healthcare, and technology. The company's extensive portfolio is utilized in critical research, development, and production activities at over 300,000 customer locations across 180 countries.

As Avantor continues to innovate and expand, the addition of Jerry Porreca to the executive team underscores the company's dedication to maintaining the highest standards of quality and regulatory compliance in serving its global customer base.

You may also be interested in:
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.